Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers children aged one to ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological <a target=_blank ...

Dupixent (dupilumab ... Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may ...

An archive and transcript of this call will be available on the Regeneron investor relations website shortly after ... the continued strong performance of Dupixent, continued growth for Libtayo ...

Our presentation today including our earnings press release issued earlier today and our SEC filings are available on our ...

Operator: Good afternoon, and welcome to AbCellera’s Q3 2024 Business Update Conference Call. My name is Tamiya, and I will ...

Our presentation today including our earnings press release issued earlier today and our SEC filings are available on our Investor Relations website ... of which DUPIXENT is the big one.

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.